AnteoTech Limited (ADO) Earnings Call Transcript & Summary
February 26, 2025
Earnings Call Speaker Segments
Moderator
operatorWebinar. I'm Alex Paul, calling in from InvestorStream, and I'll be hosting you today. Joining us to present is David Radford, Managing Director of AnteoTech, who will talk us through the company's half-yearly report release covering the six months ending 31 December 2024. You can find a copy of the presentation on the ASX, and later today a replay of this webinar will also be posted on AnteoTech's website along with its social media platforms. Now I'd like to hand things to David to get us started. David, over to you.
David Radford
executiveThanks, Alex, and it's good to have this chance once more. Good afternoon, everyone. I'm David Radford, CEO and Managing Director of AnteoTech, and I'm pleased to give the following review of the first half of financial year 2025. Our company concentrates on commercializing technologies that deliver cost-effective performance improvements in both clean energy technology and life sciences. We have several revenue opportunities across both divisions, and we're focused on diversifying customer markets. Strong IP protection exists alongside scalable business models in both teams. Revenue has risen 74% versus last year, and we're seeing solid engagement with a variety of partners in both business segments. Our use of validated data has strengthened credibility and engagement with partners, and the evaluations under way are, in many cases, reaching a point where commercial agreements are near finalization. As was advised at the AGM, the company keeps working with Mercedes and other EV manufacturers as they seek to develop their next-generation battery solutions, along with a range of other battery companies and technology companies. At the same time, we're taking a portfolio approach to the clean energy tech market.
David Radford
executiveWe are observing participation from companies in consumer electronics, healthcare, and specialty chemicals. Thanks to this broadening, we can concentrate on accelerating revenues via development opportunities involving AnteoX and UltraNode, while also through AnteoX sales. Those higher revenues and robust sales funnels were accomplished even as we kept lowering the business's operating expenses, with costs down a further 25% versus the corresponding period a year earlier. To sum up how wide-ranging the operational accomplishments are, the company keeps making solid strides in both of its focused divisions, with commercial momentum, along with efforts underway at the corporate level, among them the naming of Fabian Beck as the company's first International Vice President of Sales. The lithium-ion battery market keeps expanding, and appreciation is rising for why more silicon in the anode matters — both for delivering better performance in terms of energy density and for the ability to diversify and de-risk battery supply chains. That consideration carries weight because 70% of the graphite used worldwide today comes from China. Recognition of both these advantages is now emerging as the shift toward greater use of silicon anodes proceeds. Within the life sciences business, the Indian strategy is producing revenue growth.
David Radford
executiveIndia's Health for All program is expected to push the diagnostics market there from roughly $13 billion in 2023 to over $26 billion by 2028. A large share of that expansion should stem from point-of-care advances, and AnteoTech is positioned strongly to capture this opportunity. Looking at how the clean energy business has progressed and where it stands in the market, we've delivered an impressive result of 900 cycles with 70% energy retention, using an anode whose energy content exceeds that of a comparable graphite anode by more than two times. Those results let us pursue consumer electronics markets right now, and although we stay focused on hitting the 1,000-cycle and 80% energy retention goal, our present capability is prompting a variety of battery companies and electric vehicle makers to engage with AnteoTech as they seek to make this shift toward raising silicon content in their anodes. Our sales funnel keeps expanding across multiple market segments. As I mentioned earlier, these include consumer electronics, advanced chemistries, and electric vehicles. We've made headway with a number of companies that are expected to turn into commercial engagements in the near term. Every company we are working with is seeking performance gains, that is, more cycling or greater energy density with ideally lower input costs.
David Radford
executiveWhat we keep concentrating on is achieving the lowest delivered cost per kilowatt hour. Ever since Fabian Beck, our International Vice President of Sales, joined the company, our sales funnel has grown. At this point Manuel and Fabian are both engaging through extensive networks inside numerous companies, and we are witnessing encouraging involvement in those targeted opportunities. As we mentioned on the earlier slide, a lot of these opportunities are wrapping up thorough evaluations, with commercial talks, proposals turned in, and discussions in progress. For AnteoTech, the Indian emphasis is not just within the clean energy division, where we are in early talks with a variety of battery companies — it is also a major catalyst for growth in life sciences for us. The partnership with Serum Institute keeps growing, and demand for AnteoBind keeps rising. At the same time, the outcomes we are producing from the Vidcare evaluation have been highly encouraging. Several additional companies are right now evaluating AnteoBind NXT for deployment across a variety of diagnostic products, and our focus stays on helping our distribution partner bring these to completion and on creating future revenue streams. To sum up the goals for success, the company is pursuing this broadening of customer opportunities across both business units.
David Radford
executiveWe're aiming to finalize a number of clean energy opportunities soon, and the sales resources are now in place to push those through to completion. The life science opportunities in India keep progressing, and together with our distribution partner we're working to increase uptake of AnteoBind. We're also continuing to direct internal investment toward areas of the company that will bring in short-term revenues for the business. As I wrap up this presentation, there are several key points I'd like to leave with you. First, revenues are on the rise, and we have multiple commercial milestones in our sights. Second, we keep producing compelling, validated data in support of our clean energy offerings. Assuming we go on meeting the KPIs we've mutually agreed, we've identified routes to commercial agreements that are already under discussion. Third, and this matters, our life sciences revenues are climbing, and we have multiple growth opportunities ahead there, just as we do in clean energy. I'd like to end the presentation at that point, Alex. I want to thank our shareholders for their support and interest, and I'd be glad to take any questions shareholders may have submitted.
Moderator
operatorYes, thank you, David. So, aside from the appointment of Fabian Beck, which you brought up in the presentation, the first question we've received is whether AnteoTech has made any additional moves to grow its physical footprint in Europe or North America.
David Radford
executiveYes, so Fabian joined the team at the start of December, and his focus is on drawing on the broad sales networks he brings and pushing the sales opportunities we already have through to completion. We're backing those efforts with internal resources out of Brisbane, but as revenue grows in both Europe and North America, it's quite likely that our physical footprint will expand in those regions so we can serve customers better.
Moderator
operatorThanks, David. Is the life science division now testing AnteoBind NXT in uses beyond vaccines and POC tests?
David Radford
executiveWe have found a number of promising opportunities beyond what we're doing in vaccine development and point-of-care testing. Still, at this point in commercialization, it matters that we stay entirely focused on pushing the opportunities we have now to grow revenues. Yes, we have found them. They are interesting, but what we're really concentrating on at the moment is point-of-care testing and operating inside the vaccine market.
Moderator
operatorSwitching over to Mercedes — does Mercedes's continuing assessment of AnteoX stand apart from their UltraNode testing, or have they begun weighing AnteoX as part of that UltraNode evaluation?
David Radford
executiveThat's a really solid question. So, let me make sure we frame this properly. AnteoX plays an essential role inside UltraNode. Whenever a customer is assessing UltraNode, they're inevitably going to be assessing AnteoX too, since it's a component of that offering. That's the first point worth distinguishing. Mercedes bought UltraNode to incorporate into their testing and validation network. From what we understand, the AnteoX supplied to them is being applied in an evaluation of how manufacturable their own proprietary anodes are. To the best of our knowledge, both of those evaluations are progressing favorably, and we're still enthusiastic about what's possible with Mercedes.
Moderator
operatorAt what point does AnteoTech anticipate that the UltraNode patent will be granted?
David Radford
executiveOur shareholders are certainly aware, I believe, that we have filed patent applications for the UltraNode product. That patent process is currently in progress, and until the patent is actually granted, we cannot provide any guidance regarding the date of formal approval.
Moderator
operatorThanks, David. And last thing from me: is the company going after businesses that could reach the market more quickly than the EV space, where validation takes longer?
David Radford
executiveLike I mentioned in the presentation, we've been pursuing a portfolio strategy for the past couple of years. Our approach to the market is broad, covering consumer electronics, specialty chemical companies, and battery manufacturers within these segments. Having this diversified approach gives us a variety of opportunities to capture the nearer-term revenue opportunity. As we've noted, several evaluations are currently in progress, and we hope to share news of progress soon. Yes, we are going after a range of companies that differ in their speed to market. Yes.
Moderator
operatorGreat. Thanks to each of you for being here with me. I should mention as well how impressive the attendance is at today's webinar — something I personally value, and clearly the AnteoTech team does too. My thanks also go out to David for making time to present to us and for fielding a few of our questions. So, David, before I wrap things up with you, is there anything else you'd like to say to close us out today?
David Radford
executiveAbsolutely, Alex — first of all, I want to express our gratitude to the shareholders for the support they keep giving us. As I've said, we're quite optimistic that some interesting news flow will come our way in the near term. Once more, thank you for all of that support. And Alex, thank you as well for giving us this chance to present.
Moderator
operatorThanks, David. As I said earlier, a recording of the webinar will be posted on AnteoTech's website and social media platforms later today. The presentation is also accessible on the ASX. That's all from us here. Thank you, everyone. Have a great day.
David Radford
executiveAppreciate that, Alex.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete AnteoTech Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to AnteoTech Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in AnteoTech Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.